258532-76-2

Basic information

• Product Name: 8-HYDROXY-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE
• Synonyms: 8-HYDROXY-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE;8-Hydroxy-2H-1,4-benzoxazin-3(4H)-one;8-Hydroxy-3-oxo-3,4-dihydro-2H-1,4-benzoxazine
• CAS NO: 258532-76-2
• Molecular Formula: C₈H₇NO₃
• Molecular Weight: 165.147
• Mol File: 258532-76-2.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 8-HYDROXY-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 8-HYDROXY-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE(258532-76-2)
• EPA Substance Registry System: 8-HYDROXY-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE(258532-76-2)

Safety Data

• Hazardous Substances Data: 258532-76-2(Hazardous Substances Data)

Usage

General Description

8-HYDROXY-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE, also known as oxazinone, is a chemical compound with the molecular formula C8H5NO3. It is a heterocyclic compound containing both nitrogen and oxygen atoms in its six-membered ring structure. Oxazinone is a synthetic intermediate used in the production of pharmaceuticals and agrochemicals. It is also used as a building block in organic synthesis to create various compounds with diverse biological activities. Oxazinone derivatives have been studied for their potential as antitumor, antibacterial, and antiviral agents, making them an important area of research in medicinal chemistry. The compound's structure and properties make it a valuable tool for drug discovery and development.

Upstream product

• 258532-71-7 8-methoxy-4H-benzo[1,4]oxazin-3-one 
• 90-05-1 2-methoxy-phenol 
• 40925-71-1 2-amino-6-methoxyphenol 
• 15969-08-1 6-methoxy-2-nitrophenol 
• 888731-91-7 2-chloro-N-(2-hydroxy-3-methoxyphenyl)-acetamide 
• 107-83-5 2-Methylpentane 
• 20734-66-1 1,2-dihydroxy-3-aminobenzene 

Downstream Products

• 258532-30-8 methyl (4-(2-(1,1-diphenyl-2,2,2-trifluoroethylthio)ethyl)-3,4-dihydro-2H-1,4-benzoxazin-8-yloxy)acetate 
• 258532-31-9 methyl (4-(2-(1,1-bis(4-fluorophenyl)ethylthio)ethyl)-3,4-dihydro-2H-1,4-benzoxazin-8-yloxy)acetate 
• 258532-38-6 methyl (4-(2-(1,1-diphenylethylthio)ethyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yloxy)acetate 
• 258532-33-1 methyl (4-(2-(2,2-diphenylpropylthio)ethyl)-3,4-dihydro-2H-1,4-benzoxazin-8-yloxy)acetate 
• 258532-29-5 methyl (4-(2-(1,1-diphenylethylthio)ethyl)-3,4-dihydro-2H-1,4-benzoxazin-8-yloxy)acetate 
• 258532-36-4 methyl (4-(2-(1,1-diphenylethoxy)ethyl)-3,4-dihydro-2H-1,4-benzoxazin-8-yloxy)acetate 
• 258532-84-2 8-acetoxy-4-(4,4-diphenylpentyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazine 
• 258532-83-1 8-acetoxy-4-(2-(1,1-diphenylethoxy)ethyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazine 
• 258532-28-4 methyl (4-(2-(diphenylmethylthio)ethyl)-3,4-dihydro-2H-1,4-benzoxazin-8-yloxy)acetate 
• 881830-06-4 acetic acid 4-(4,4-diphenyl-pentyl)-3,4-dihydro-2H-benzo[1,4]oxazin-8-yl ester 
• 881830-05-3 acetic acid 4-[2-(1,1-diphenyl-ethoxy)-ethyl]-3,4-dihydro-2H-benzo[1,4]oxazin-8-yl ester 
• 258532-32-0 methyl (4-(2-(1-methyl-1-phenylethylthio)ethyl)-3,4-dihydro-2H-1,4-benzoxazin-8-yloxy)acetate 
• 258532-89-7 4-(4,4-diphenylpentyl)-8-hydroxy-3-oxo-3,4-dihydro-2H-1,4-benzoxazine 
• 881830-02-0 [4-(2-benzylsulfanyl-ethyl)-3,4-dihydro-2H-benzo[1,4]oxazin-8-yloxy]-acetic acid methyl ester 

Relevant articles and documents

Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.

Nitrogen-containing fused ring compounds and use thereof

A URAT1 activity inhibitor containing a nitrogen-containing fused ring compound represented by the following formula [1]: wherein each symbol is as defined in the description. The present invention is useful for the prophylaxis or treatment of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like.

Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases

Compounds of the general formula (I): wherein the variables are as defined in the specification are useful for the prophylaxis or treatment of serotonin-related, especially 5-HT2receptor-related, diseases in human beings or animals, particularly diseases related to the 5-HT2creceptor, especially diseases such as eating disorders, memory disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctionions, and urinary disorders.